Teva abandons Ajovy trial for cluster headaches
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read Moreby Anna Smith | Apr 24, 2019 | News | 0
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read Moreby Selina McKee | Mar 11, 2019 | News | 0
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Read Moreby Selina McKee | Sep 28, 2018 | News | 0
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
Read Moreby Selina McKee | Jun 18, 2018 | News | 0
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
Read Moreby Selina McKee | Jun 12, 2018 | News | 0
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Read Moreby Selina McKee | Apr 18, 2018 | News | 0
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Read Moreby Selina McKee | Feb 7, 2018 | News | 0
The first of two pivotal Phase III clinical trials evaluating Allergan’s experimental anti-CGRP migraine drug ubrogepant has met its key goal.
Read Moreby Selina McKee | Dec 12, 2017 | News | 0
US regulators have accepted for review Eli Lilly’s investigational non-opioid pain drug galcanezumab for the prevention of migraine.
Read Moreby Selina McKee | Nov 30, 2017 | News | 0
The New England Journal of Medicine has published two separate studies showing that CGRP-targeting therapies – namely Novartis’ erenumab and Teva’s fremanezumab – significantly cut the number of headache days in patients with episodic or chronic migraine, respectively.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
